BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but managed on a bottom-up basis, with a focused c 20–35 stock portfolio.
Investment Companies |
Update
Investment Companies |
Update
Investment Companies |
edison tv
Investment Companies |
Review
Claude Mikkelsen
Director of IR
Daniel Koller
Head of investment management
Dr Silvia Siegfried-Schanz
Director of IR
Erich Hunziker
Chairman
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 6.1 | (4.6) | (35.0) |
Relative | 1.4 | (1.9) | (33.3) |
52 week high/low | CHF60.7/CHF35.6 |
BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. BION is the largest biotech investor among its investment company peers. It invests in high-quality biotech assets that target substantial market opportunities. BION’s managers are optimistic about the outlook for the sector. They believe sentiment towards the sector should improve as interest rates peak and begin to decline. Meanwhile, they expect to see ongoing fundamental progress by portfolio holdings, with several due to reach key regulatory, clinical or commercial milestones over coming months. In addition, historically low valuations have created opportunities to add or top up exposure to interesting companies at attractive prices. BION differentiates itself from its peers by its highly competitive dividend policy – it pays a dividend equivalent to 5% of the average share price over December each year.